我們已在上線！進一步了解

Transmedics

TMDX

市值 US$24.5億

70.78 USD

-5.74

7.5%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

70.78

0.00

0%

1天

-7.5%

5天

-8.89%

1個月

-19.16%

3個月

-6.87%

6個月

-35.14%

今年迄今

-42.31%

1年

-38.81%

5年

168.82%

10年

216.55%

關於： TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

員工： 898

醫療保健醫療器材

新聞

正面

中性

負面

市場情緒 3個月

正面 12.5%

中性 75%

負面 12.5%

TransMedics Offers An Attractive Entry Point, With Upside Potential Outweighing Risks

TransMedics is a market-changing player in organ transplant technology, with a unique multi-organ perfusion platform and integrated logistics network. TMDX earns a buy rating as recent pullbacks, driven by margin volatility due to higher investments, present an attractive entry point for long-term investors. Key growth drivers include the upcoming kidney OCS product (potential FDA submission in 2027) and international expansion, targeting $2B+ revenue by 2032.

TransMedics Offers An Attractive Entry Point, With Upside Potential Outweighing Risks

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no costor obligation. We would handle any matter on a contingent fee basis, whereby you would notbe responsible for out-of-pocket payment of our legal fees or expenses.

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

TransMedics: Waiting On 2027 Catalysts (Rating Upgrade)

TransMedics' liver growth is moderating, increasing the company's dependence on international markets and heart, lung, and kidney to sustain growth. Heart and lung trial delays have created uncertainty, but successful completion in 12–18 months could reignite momentum. The long-term opportunity remains substantial, particularly OCS Kidney, but execution across new indications and Europe is increasingly critical to supporting TransMedics' valuation.

TransMedics: Waiting On 2027 Catalysts (Rating Upgrade)

The Motley Fool

2 Stocks Down 28% and 34% to Buy and Hold

TransMedics Group's investments are currently lowering margins, but they could eventually boost revenue and profits. SoFi Technologies is facing some near-term uncertainty, but the company's long-term prospects remain attractive.

2 Stocks Down 28% and 34% to Buy and Hold

TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into TransMedics Group, Inc. (NasdaqGM: TMDX) (“TransMedics” or the “Company”).TransMedics is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. The Company operates the Organ Care System, or.

TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX

TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook

ANDOVER, Mass., Sept. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief Financial Officer, effective September 21, 2026.

TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Zacks Investment Research

Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?

TransMedics' rapid revenue growth and cheaper valuation face rising margin pressure as heavy investment raises execution risks.

Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?

Zacks Investment Research

Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?

Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?

查看新聞排名

價格圖表採用Lightweight Charts™實作